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SUMMARY Atopic dermatitis is a chronic relapsing inflammatory 
skin disease the incidence of which has been constantly growing 
in all age groups. Research into the use of naphthalene in the 
treatment of patients with psoriasis proved its anti-inflammatory 
and antiproliferative effects as well as a satisfactory remission 
for months in more than 70% of treated patients with psoriasis. 
The present study was undertaken to investigate the efficacy of 
naphthalene in the treatment of patients with atopic dermatitis. 
According to study results, naphthalene therapy proved efficacious 
and free from side effects in 20 atopic dermatitis patients.
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INTRODUCTION
 Naphthalene therapy for atopic dermatitis (AD) 
was assessed at Naftalan Special Hospital for 
Medical Rehabilitation in Ivanić Grad. Naphthalene 
is natural earth mineral oil, a dense, dark-brown 
liquid with a high specific weight (0.93-0.98 at 15 
°C). As heavy oil, it is found in surface earth layers 
(100-700 m) (1-5). Naphthalene consists of a small 
quantity of light fractions (petrol, ligroin, kerosene) 
and paraffin, and a high percentage of polycyclic 
naphthol hydrocarbons  (cyclopentanoperhydro-
phenantrene) structures. Sterans are most sig-
nificant as carriers of the naphthalene medicinal 
properties. Sterans have a chemical structure sim-
ilar to hormones and vitamins. The size of its mol-
ecule is 200-450 Da, which makes possible for the 
molecule to pass through the healthy (500 Da) and 
diseased (700 Da) skin (2,5-8). Naphthalene as a 
natural medicinal product with proven efficacy and 
antiproliferative properties in psoriasis (3,4-8), and 
as an antiangiogenic factor in psoriatic lesions (9). 
A new naphthalene preparation, naphthalene AA-
final (Ivalan), enriched with sterans, constituents 
believed to represent active naphthalene com-
ponents, while the content of polyaromatics has 
been substantially reduced, is currently available 
at Naftalan Special Hospital for the management 
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of psoriasis (10). Naphthalene therapy as one of 
newest topical AD treatments was assessed in the 
present study. 
MATERIAL AND METHODS
 The study included 20 AD patients (9 male and 
11 female), aged 15-65, most of them in the 15-
25 age group. Study patients presented various 
clinical pictures of AD. Clinical evaluation accord-
ing to SCORAD index (11) and photographing 
were done before and after therapy. Biochemistry 
laboratory testing including complete blood count 
(CBC), erythrocyte sedimentation rate (ESR), 
blood glucose (BG), aminotransferases, alkaline 
phosphatase (AP), albumin, bilirubin, creatinine, 
cholesterol, triglycerides (TG), blood urea nitro-
gen (BUN) and serum electrolytes, urinalysis and 
histologic evaluation were performed before and 
after 3 weeks of therapy. Total serum IgE levels 
were quantitatively determined using the CAP 
system techniques.
 Naphthalene therapy was administered ac-
cording to the usual protocol, applied for some 15 
years in the treatment of patients with psoriasis and 
rheumatic diseases at Naftalan Special Hospital 
for Medical Rehabilitation in Ivanić Grad, Croatia. 
Naphthalene therapy was applied once daily with 
warm baths for 12-14 minutes in tubs with naphtha-
lene oil, at a temperature of 34-38 °C, for 3 weeks. 
After bath, neutral creams (Eucerin intensive cream 
or Belobaza cream and Eucerin cream shower oil) 
were applied. An oral antihistaminic (diphenhydr-
amine, Dimidril, 3x1 tbl) was used occasionally. 
 
RESULTS
Clinical evaluation after 3 weeks of naphthalene 
therapy revealed improvement of clinical assess-
ment in all cases (Figs. 1-6), along with a reduc-
tion of itching and sleeping disturbance. The mean 
SCORAD index was 75.4 before and 30.9 after 
naphthalene therapy. Graphic records of SCO-
RAD index are shown in Fig. 7.
Figure 4. Atopic dermatitis in patient K. O. after 
3-week naphthalene therapy.
Figure 1. Atopic dermatitis in patient R. M. before 
naphthalene therapy.
Figure 2. Atopic dermatitis in patient R. M. after 
3-week naphthalene therapy.
Figure 3. Atopic dermatitis in patient K. O. before 
naphthalene therapy.
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 Histological evaluation
 Probatory excisions were done in all 20 patients 
before and after 3-week naphthalene therapy. In 
11 patients, AD could not be identified on control 
histology findings, whereas in nine patients control 
histology findings showed acanthosis (epidermis 
widening) to be the same or reduced.  Subepider-
mal perivascular infiltrate of lymphocytes and fibro-
histiocytes was reduced or highly reduced (Figs. 
8a, 9a). Reduction of inflammatory infiltration was 
observed in all 20 patients (Figs. 8b-10b). 
Figure 5. Atopic dermatitis in patient S. M. before 
naphthalene therapy.
Figure 6. Atopic dermatitis in patient S. M. after 
3-week naphthalene therapy.
Figure 7. Graphic record of SCORAD index in 20 
atopic dermatitis patients before and after naph-
thalene therapy.
Figure 8. (a) Patient R. M. before naphthalene 
therapy: parakeratosis, acanthosis and inflamma-
tory infiltration in the subepidermal dermis (HE; 
X220); (b) patient R. M. after 3-week naphthalene 
therapy: acanthosis and reduction of the inflam-
matory infiltration (HE; X220).
IgE evaluation
Total IgE level was higher after than before naph-
thalene therapy in only four, unchanged in six and 
reduced in ten of 20 AD patients (Table 1).
Biochemistry laboratory parameters 
In all 20 patients, the values of CBC, ESR, BG, 
aminotransferases, AP, albumin, bilirubin, cre-
atinine, BUN, serum electrolytes, calcium, cho-
lesterol, TG and urinalysis determined before 
and after 3-week naphthalene therapy were 
within the normal range. The naphthalene min-
eral earth oil caused no hematotoxicity, hepa-
totoxicity or nephrotoxicity in AD patients. 
DISCUSSION
 In all 20 patients, clinical improvement in terms 
of reduction or disappearance of pruritus and sleep 
disturbance, reduction of skin lesions and reduc-
tion of SCORAD index (changes in total intensity, 
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Patient 
No. 





1 37 k IU/L  (122) 70 k IU/Ll (122)
2 1117 IU/mL (120) 552.6 IU/mL (120) 
3 144 IU/mL 130 IU/mL
4  85 IU/mL 85 IU/mL 
5  88 k IU/L    88 k IU/L
6  822 IU/mL 719 IU/mL
7 1329.2 k IU/L 1220 k IU/L
8  81 k IU/Ll 81 k IU/L
9 159 IU/mL 140 IU/mL
10 130 IU/mL 130 IU/mL 
11 144.1 IU/mL 144.1 IU/mL
12  619 IU/mL 2000 k IU/L 
13  210.3 IU/mL 234.6 IU/mL 
14  27.1 IU/mL  27.1 IU/mL
15 3275 IU/mL 2877 IU/mL
16 2240.60 k IU/L 2175.40 k IU/L
17 2409.0 k IU/L 2009.0 k IU/L
18 3898 k IU/L 4000 k IU/L
19 4000 k IU/L 2400 k IU/L
20 1888.0 k IU/L 1105.0 k IU/L
Table 1. Total IgE results before and after naph-
thalene therapy in 20 atopic dermatitis patients            
Figure 9. (a) Patient K. O. before naphthalene 
therapy: acanthosis and inflammatory infiltration 
in the upper part of the dermis (HE; X220); (b) 
patient K. O. after naphthalene therapy: acanthosis 
and reduction of the inflammatory infiltration (HE; 
X220).
i.e. erythema, edema, excoriation, lichenification 
and crusts) was recorded (11). Tolerability was 
good and free from side effects or alterations in 
hematology and biochemistry parameters. In our 
20 patients, remission lasted for a mean of 20.4 
months. Naphthalene proved to be a good thera-
peutic option in AD patients with a 70% efficacy. 
Considering that naphthalene is a non-steroidal 
therapy, we can recommend it in the treatment 
Figure 10. (a) patient S. M. before naphthalene therapy: subepidermal inflammatory infiltration (HE; 
X180); (b) patient S. M. after naphthalene therapy: reduction of the inflammatory infiltration (HE; X220).
of AD in both adults and children. Naphthalene 
therapy is one of therapeutic options for AD and 
is harmless for health in general. No unwanted ef-
fects that would require discontinuation of naph-
thalene therapy were recorded. Naphthalene 
therapy offers a new therapeutic approach in the 
management of AD.
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Radeiner, mineral water; year 1937.
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